Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of NPT189 in Healthy Subjects
NCT03610035Phase 1Completed
- Sponsor
- Proclara Biosciences
- Start
- Jul 2018
- Primary completion
- Feb 2019
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in systemic amyloidosis comparing NPT189 with Placebo (2 arms). Primary endpoint: Safety of a single intravenous (IV) infusion of NPT189 (subjects experiencing adverse events) at Day 49. Started Jul 2018; status: completed.
02
Drugs
PCS-01
03
Conditions
systemic amyloidosis
Beyond the preview
Go deeper on NCT03610035.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03610035.